Imagine needing strong pain medicine and being handed a document that looks half like a lease, half like a probation form.
That, in a nutshell, is a narcotic treatment contract, also called an opioid treatment agreement,
or more informally, a “pain contract.” It’s a tool that’s become increasingly common in chronic pain management,
especially in the United States, as clinicians try to balance compassion with the realities of an opioid crisis.

But here’s the uncomfortable question at the heart of science-based medicine:
Do these contracts actually work the way we hope they do?
Or are they more of a ritual that makes clinicians feel safer without clearly improving outcomes?

In this article, we’ll unpack what narcotic treatment contracts are supposed to do, what they actually do (according to the evidence),
and how patients and clinicians can approach them in a way that’s more ethical, humane, and aligned with real data rather than wishful thinking.

What are narcotic treatment contracts, really?

A narcotic treatment contract is a written agreement between a patient and a prescriber that outlines the rules, expectations,
and responsibilities involved in using prescribed opioid medications for chronic pain.
These agreements are often recommended by pain societies, licensing boards, and state authorities as part of “safe opioid prescribing.”

Although the details vary, most contracts include clauses like:

• Agreeing to receive opioid prescriptions from one prescriber and often one pharmacy.
• No early refills, no replacements for “lost” or “stolen” prescriptions, and no dose changes without discussion.
• Consent to urine drug screening (random or scheduled) and prescription drug monitoring program (PDMP) checks.
• Commitment not to share medications and to keep them stored safely.
• Clear conditions under which the prescriber may taper or discontinue opioids, such as evidence of misuse or unsafe behavior.

Sample contracts from medical boards and health departments emphasize functional goals (like working or doing daily activities),
safe storage, and specific behaviors that will end the prescribing relationship if violated.
They’re framed as tools to support shared understanding and safety, not as punishment.

Why did pain contracts become so popular?

Narcotic treatment contracts grew up at the intersection of two major trends:

1. Expanding opioid prescribing for chronic noncancer pain in the 1990s and early 2000s.
2. Rising awareness of opioid misuse, overdose, and diversion, followed by intense regulatory scrutiny.

From a purely theoretical standpoint, these contracts seem reasonable:

• They create clear expectations around safe use.
• They document informed consent and the risks of opioids.
• They give clinicians something to point to if prescribing has to be limited or stopped.
• They may help detect concerning behaviors earlier, especially when combined with urine drug testing and PDMP checks.

Early commentaries in the pain literature framed contracts as “common sense” tools:
low-cost, easy to implement, and ethically appealing as long as they were applied consistently and fairly.
Over time, state guidelines and institutional policies began to describe treatment agreements as either
“best practice” or a strongly recommended part of long-term opioid therapy.

The science part: what does the evidence actually say?

When you move from theory to data, the picture becomes much murkier.
Several systematic reviews and professional commentaries have tried to answer a basic question:
Do narcotic treatment contracts reduce opioid misuse or improve outcomes in chronic pain?

Systematic reviews: weak signals, modest quality

Early reviews of opioid treatment agreements found only a small number of studies,
most of them observational, uncontrolled, or otherwise methodologically limited.
The general conclusion: at best, there is weak evidence that treatment agreements and urine drug testing
reduce opioid misuse or aberrant behaviors.

Later reviews, including those looking specifically at “patient-prescriber agreements,”
have essentially echoed the same message. Overall quality of evidence is low to very low,
with small sample sizes, inconsistent definitions of “misuse,” and a heavy reliance on clinic-based populations
that may not represent real-world diversity in pain care.

In other words, if narcotic treatment contracts were a new drug, the data supporting them would
not remotely meet the bar for FDA approval.

Do contracts reduce misuse, overdose, or addiction?

So far, research has not shown that contracts consistently lower rates of:

• Opioid misuse or “aberrant drug-related behaviors”
• Overdose events
• Transition to opioid use disorder

Some studies report modest reductions in emergency department visits or requests for early refills
when contracts and urine drug testing are part of a broader opioid management program.
But teasing out the unique impact of the contract itself is almost impossiblethese programs typically include multiple interventions,
such as closer follow-up, dose limits, PDMP checks, and non-opioid pain strategies.

That’s a crucial nuance: the contract is just one piece of a much larger clinical and policy environment.
Blaming or praising the contract alone oversimplifies what’s actually happening.

What about clinician satisfaction and clinic workflow?

Interestingly, some of the more consistent findings are not about patient outcomes at all, but about clinician experience.
Many prescribers report that using opioid treatment agreements:

• Makes them feel more comfortable and in control when prescribing opioids.
• Gives them a clearer framework for discussions about risks and expectations.
• Can reduce conflicts over early refills and dose escalation by “externalizing” the rules.

From a science-based medicine perspective, it’s perfectly valid to acknowledge that documentation tools
can improve clinician comfort and workflow. But that’s different from proving that they improve patient-centered outcomes,
such as pain control, function, safety, or quality of life.

Potential harms and unintended consequences

Contracts are often introduced as “routine paperwork,” but patients do not necessarily experience them as neutral.
Several qualitative studies and commentaries have raised concerns that narcotic treatment contracts can:

• Feel coercive, especially when presented as non-negotiable: “Sign this or you don’t get medication.”
• Reinforce stigma, sending the message that the patient is presumed untrustworthy or likely to misuse drugs.
• Discourage honesty about substance use, mental health, or financial stressors if patients fear being cut off.
• Disproportionately impact marginalized patients, who may already face discrimination and barriers to care.

Patients in some surveys describe increased anxiety about “breaking a rule,” even unintentionally,
and fear that a single misstep will mean abrupt loss of pain control.
For people already living with debilitating pain, that fear can be overwhelming.

There’s also a concern that rigid contract enforcement can lead to rapid or involuntary tapers without adequate support,
which we now know can be harmful, both physically and psychologically.
Contemporary guidelines urge clinicians to avoid abrupt discontinuation of opioids whenever possible and to
treat pain and addiction with the same level of seriousness and empathy as any other chronic condition.

How do major guidelines view treatment agreements today?

Modern U.S. opioid prescribing guidelines generally present treatment agreements as one tool among many,
not as a magic shield against misuse.

For example, national and state guidance typically emphasizes:

• Starting with non-opioid and non-pharmacologic options whenever feasible.
• Using lowest effective doses and reassessing benefits and harms regularly.
• Checking PDMP databases, especially when prescribing long-term or high-dose opioids.
• Using urine drug testing when clinically indicated, with clear discussion and follow-up.
• Considering treatment agreements for long-term therapy, especially in higher-risk situations.

Importantly, more recent guidelines stress that contracts should not be used as a weapon or a one-size-fits-all requirement.
They should be part of an individualized pain management plan that includes realistic goals, multimodal treatment,
and a path forward if opioids are not helpful or cause harm.

A science-based medicine view: plausible but unproven

Science-Based Medicine is all about balancing biological plausibility with actual evidence.
Narcotic treatment contracts land in an awkward middle zone:

• They’re plausible: it makes sense that clear rules and documented expectations might reduce chaos.
• They’re widely used and often mandated or strongly encouraged in policies.
• But the direct evidence that they significantly reduce misuse or improve outcomes is weak at best.

That doesn’t mean contracts are useless. It does mean we should be honest about what we knowand what we don’t.
Overstating their impact risks turning them into “security theater”: a visible ritual that makes clinicians and regulators
feel better while doing less than advertised for real-world safety.

A science-based approach also asks whether we’re evaluating the right outcomes.
If patients feel stigmatized, avoid care, or under-report problems because of contracts,
that’s a serious unintended harmeven if misuse rates look slightly better on paper.

How patients can navigate narcotic treatment contracts

If you are a patient with chronic pain and your clinician presents a treatment agreement,
you are allowed to do more than just sign and hope for the best. Here are practical steps:

1. Ask for plain-language explanations

Many contracts are written at a reading level higher than the average person’s comfort zone.
Ask your clinician to explain each major section in everyday language:

• “What happens if my pain flares and I run out early once?”
• “What exactly counts as ‘misuse’ in this context?”
• “What will you do if my urine test shows something unexpected?”

A science-based, patient-centered clinician should be able to answer these clearly and kindly.

2. Clarify goals beyond “less pain”

The best contracts emphasize function, not just pain scores.
Talk with your clinician about what success would look like in your life: walking the dog, going back to work,
cooking dinner without needing to lie down afterward. Connect the contract to those real-world goals.

3. Discuss non-opioid options and backup plans

A contract that only discusses what happens if you “break the rules” is incomplete.
Ask about:

• Physical therapy, behavioral therapies, diet, exercise, and sleep strategies.
• Non-opioid medications and interventional procedures when appropriate.
• A tapering plan or alternative pain strategies if opioids don’t help enough or cause side effects.

The more your care plan looks like a toolbox instead of a single pill bottle, the better.

How clinicians can use contracts more wisely (or not at all)

For clinicians, the question isn’t just “Should I use a contract?”
A more nuanced, science-based question is: “If I use one, how can I make it ethically sound and clinically useful?”

1. Make it a conversation, not a test

Introduce the agreement as part of informed consent, not as a loyalty oath.
Explain that it’s meant to create transparency and safety for both parties, not to label the patient as suspicious by default.

2. Use plain language and realistic expectations

Avoid legalese. Clearly describe what will happen if you see concerning signs: more frequent visits, closer monitoring,
discussion of addiction treatment if indicated, and a gradual, supported taper when necessary.

3. Focus on function and shared goals

Include specific, measurable functional goals in the agreement. Reassess periodically and be explicit that continued opioid therapy
depends not only on absence of misuse but also on meaningful improvement (or at least preservation) of function and quality of life.

4. Watch for bias and inequity

Be honest about the risk of applying contracts more aggressively to some groups of patients than others.
Standardize processes as much as possible, but still individualize decisions.
Document clinical reasoning, not just “contract violation = discharge.”

Real-world experiences with narcotic treatment contracts

Research gives us numbers and trends, but clinical practice is lived in stories.
While respecting privacy, we can look at common patterns that emerge in patient and clinician experiences with opioid treatment agreements.

Consider a composite patient we’ll call Maria, a 48-year-old with chronic low back pain after a workplace injury.
She’s tried physical therapy, non-opioid medications, and injections with partial relief.
Her new primary care clinician suggests a time-limited trial of long-acting opioids and introduces a treatment contract.

For Maria, the contract initially feels intimidating. She worries that one misstep will get her labeled as an “addict”
and that she’ll lose access to medication if she forgets a pill count appointment or if her urine test picks up a medication prescribed by another doctor.
But her clinician takes time to walk through each clause:

• They clarify that the goal is to help her function better at work and at home.
• They explain that unexpected urine test results are a starting point for conversation, not automatic punishment.
• They agree on a follow-up schedule and contingency plan if opioids don’t provide enough benefit.

Over several months, Maria finds that her pain is somewhat better and her function improves modestlyshe can work part-time again.
She also finds reassurance in having a written plan: she knows what to expect at each visit and what her responsibilities are.
The contract, in this scenario, supports communication instead of replacing it.

Now consider a different composite experience: James, a 56-year-old with severe osteoarthritis and a history of stable opioid use.
When his clinic shifts to a new policy, he is told he must sign a contract immediately or his prescriptions will not be renewed.
No one walks him through the document; it’s slid across the desk with a clipboard.

James signs, but leaves feeling mistrusted and anxious. Later, his urine test shows a prescribed benzodiazepine from a specialist he forgot to mention.
His clinician, worried about being flagged by regulators, abruptly stops his opioids instead of tapering.
James struggles with uncontrolled pain and withdrawal symptoms and avoids returning to the clinic.

These two stories illustrate the same tool used in very different ways.
In Maria’s case, the contract is embedded in a respectful, collaborative relationship.
In James’s case, the contract is wielded as a blunt administrative requirement that damages trust and may worsen health.

Clinicians also describe a spectrum of experiences. Some feel that agreements give them a way to set consistent boundaries
and reduce conflict around early refills. Others find that overly rigid or templated contracts get between them and their patients,
turning nuanced clinical decisions into checkbox exercises. Many worry about the legal implications: if they use a contract,
does it protect them from liabilityor create new vulnerabilities if they don’t enforce every clause perfectly?

The most constructive experiences tend to share a few features:

• The contract is introduced early as part of a comprehensive pain management plan, not a last-minute condition for refills.
• Patients are invited to ask questions and express concerns.
• The agreement is revisited and updated, not treated as a one-time signature.
• Clinicians document the context behind decisions, especially when adjusting therapy or responding to possible misuse.

On the other hand, the most negative experiences often involve:

• Sudden policy changes with little explanation.
• Contracts used mainly to signal compliance with regulations rather than to help individuals.
• Mechanical enforcement of rules without regard to clinical nuance or patient safety.
• Patients who feel they have no real choice and no voice in their care.

These patterns highlight what the evidence already hints at: narcotic treatment contracts are not inherently good or bad.
Their impact depends heavily on context, communication, and the broader system in which they’re used.
A science-based, ethically grounded approach recognizes those complexities instead of assuming the mere presence of a signed paper
will solve deep, multifactorial problems like chronic pain and opioid misuse.

Bottom line: where does the evidence leave us?

Narcotic treatment contracts sit at a challenging crossroads of pain medicine, addiction science, law, and ethics.
They’re widely used, strongly recommended in some settings, and intuitively appealing.
Yet the best available research shows only weak and limited evidence that they meaningfully reduce opioid misuse or improve safety.

From a science-based medicine perspective, that should prompt humility rather than overconfidence.
Contracts may have a roleas structured communication tools, as documentation for informed consent,
and as one element in a broader risk-mitigation strategy. But they are not a substitute for:

• Comprehensive, multimodal pain management
• Accessible addiction treatment when needed
• Non-stigmatizing, patient-centered care
• Thoughtful policy that balances safety with compassion

Used thoughtfully, a narcotic treatment contract can support clarity and trust.
Used rigidly or punitively, it can become one more barrier between people in pain and the care they deserve.

Until we have stronger evidence, the most science-based approach is to treat these contracts as optional toolsnot magic solutionsand
to keep our focus squarely on outcomes that truly matter: reduced harm, improved function, and better quality of life for patients.

If you ask people living with intractable pain what daily life feels like, many won’t say “medical care.”
They’ll say “survival.” Not because they’re dramatic, but because pain that does not respond well to standard treatment can swallow work, sleep, relationships, identity, and hope.
Then, just when relief should be the focus, many patients run into a second injury: suspicion.
They are treated like a risk profile before they are treated like a person.

This article is a call for a reset. Not a reckless free-for-all. Not “opioids for everyone, forever.”
A reset toward evidence, balance, and basic human dignity.
Because pain medicine should never become a proxy battlefield where the patient is collateral damage.
The goal is simple and overdue: stop the war against patients with intractable pain, and build care that is both safer and kinder.

Evidence Base Synthesized for This Article (U.S. Sources)

This analysis synthesizes guidance and data from major U.S. health and medical institutions, including:
CDC (guidelines and national data), FDA, HHS, NIH/HEAL, NCHS, VA/DoD, NCCIH, AHRQ evidence reviews, SAMHSA, and the AMA.
The message across these sources is more aligned than people think: individualized care, safer prescribing, no abrupt forced tapering, and broader access to non-opioid and multidisciplinary pain treatment.

The Problem We Keep Missing

America can hold two truths at once:
we have had a devastating overdose crisis, and we also have millions of people with severe chronic pain who need competent, compassionate treatment.
Trying to solve one by ignoring the other is like fixing a roof by removing the floor.
Technically, something changed. Practically, everyone is still getting soaked.

Intractable pain is not “ordinary discomfort.”
It can include severe neuropathic pain, failed-back syndrome, complex regional pain syndrome, advanced arthritis, connective tissue disorders, severe spine disease, and post-surgical pain syndromes that persist despite multiple therapies.
Patients with these conditions are often highly motivated, treatment-engaged, and exhausted.
They are not asking for euphoria; they are asking to walk, parent, work part-time, or sleep through the night.

What the Evidence Actually Says (Not the Internet Rumor Version)

1) Guidelines are meant to guide, not punish

National prescribing guidance emphasizes flexibility and patient-centered judgment.
It is not intended to be used as rigid law, blanket dosage ceilings, or one-size-fits-all enforcement.
Translating guidance into hard caps can fracture care and produce exactly what medicine is supposed to avoid: preventable harm.

2) Rapid, forced tapering can be dangerous

Federal safety communications and clinician guidance repeatedly caution against abrupt opioid discontinuation in physically dependent patients.
Why? Because withdrawal, pain flares, psychological distress, and destabilization can follow.
In the worst cases, people seek unsafe alternatives, disengage from care, or face crisis-level outcomes.
A taper, when appropriate, should be collaborative, gradual, and clinically supervised.

3) Non-opioid and nonpharmacologic treatments matterbut access is uneven

Exercise therapy, CBT, multidisciplinary rehabilitation, mindfulness-based interventions, and selected procedures can improve pain and function for many conditions.
That is great news.
But “effective for many” is not “effective for everyone,” and insurance barriers often block access to exactly the alternatives guidelines recommend first.
Patients are too often told, “Try non-opioid care,” while their plan covers little beyond a pamphlet and a co-pay high enough to make yoga feel like a luxury vehicle.

4) Innovation is real, but not instant

New non-opioid pain medicines and research pipelines are promising, and this progress should be celebrated.
But innovation does not erase current suffering overnight.
Patients in pain today cannot be asked to wait politely for tomorrow’s perfect protocol.
Transition planning must include what exists now: multimodal care, individualized medication strategies, and continuity.

Why Patients With Intractable Pain Feel Criminalized

Many patients describe a repeating pattern:
they follow treatment plans, pass screening, keep appointments, try physical therapy, try behavioral tools, reduce dose when possibleand still get treated like “presumed guilty.”
Clinics close. Prescribers retire or stop pain care entirely.
Pharmacies hesitate to fill legitimate prescriptions.
Prior authorizations stall treatment for days or weeks.
Each delay is a fresh pain spike with paperwork on top.

Here is the uncomfortable reality: stigma can be baked into workflow.
A patient can do everything “right” and still be denied continuity because the system is designed around risk optics, not clinical nuance.
When that happens, we call it “policy compliance.”
Patients call it what it feels like: abandonment.

A Better Framework: Safety and Dignity Are Not Opposites

Pillar 1: Treat pain as a whole-person condition

Pain is biological, psychological, and social.
High-quality care should include functional goals (mobility, sleep, cognition, daily activity), not pain score alone.
Ask what matters to the patient: “Can you cook dinner?” “Can you sit through class?” “Can you make it through a work shift?”
Improvement in life participation is a meaningful clinical endpoint.

Pillar 2: Make multimodal treatment actually available

“Try alternatives first” must come with real coverage:
physical therapy, pain psychology, occupational therapy, interventional options when indicated, and structured self-management education.
If insurers deny these while simultaneously pressuring dose cuts, that is not stewardship.
That is cost-shifting disguised as safety.

Pillar 3: Practice opioid stewardship, not opioid prohibition

For some patients, opioids are inappropriate.
For others, they are one component of a broader plan with measurable benefit.
Good stewardship means:
start with clear goals, use the lowest effective dose, reassess benefit-risk over time, check for interactions, co-prescribe risk mitigation when indicated, and adjust gradually.
Prohibition thinking ignores heterogeneity and pushes clinicians into defensive medicine.

Pillar 4: Reduce risk without humiliating patients

Safety toolsmonitoring, follow-up visits, treatment agreements, toxicology when clinically appropriateshould be used to improve care, not punish.
Tone matters.
A respectful conversation protects trust.
A suspicious interrogation destroys it.
Trust is not “soft”; it is a clinical asset linked to adherence, disclosure, and better outcomes.

Pillar 5: Use language that lowers stigma

Language changes behavior.
Replacing labels with person-first terms is not political correctness; it is therapeutic hygiene.
If documentation frames people as problems to manage rather than humans to treat, clinical decisions follow that bias.
Respectful language supports better engagement, safer disclosure, and earlier intervention when risk rises.

What Policymakers, Health Systems, and Payers Must Do Next

1) Ban policy-level forced tapering and hard dose ceilings

Policy should support clinician judgment and individualized plans.
Blanket limits ignore diagnosis, response history, comorbidities, and patient stability.
A one-size-fits-all taper is like one-size-fits-all shoes: technically possible, practically painful.

2) Measure what matters

Stop rewarding systems only for lower prescribing totals.
Also measure function, quality of life, access to multimodal care, continuity of care, emergency visits, and patient-reported outcomes.
If “success” leaves patients less functional and more desperate, that is not success.

3) Expand pain workforce capacity

Primary care clinicians are doing heavy lifting with limited time and support.
Invest in collaborative care models that connect primary care, pain specialists, behavioral health, pharmacy, and physical medicine.
Better team structures reduce clinician burnout and improve patient safety.

4) Fix coverage gaps for non-opioid care

Multidisciplinary pain treatment should not be available only to people with premium plans, big-city ZIP codes, or flexible jobs.
Rural, disabled, and low-income patients need equal access to evidence-based options.

5) Support safer innovation while protecting current patients

New analgesics and better clinical pathways are worth celebrating.
But policy must bridge the present:
protect continuity for stable patients while improving safety standards and expanding alternatives.
Reform should reduce harm today, not in a hypothetical future.

For Families and Caregivers: What Helps Right Now

If you support someone with intractable pain, you are part of the care ecosystem.
Practical support beats pep talks.
Offer rides, medication calendar help, appointment notes, meal prep, and gentle activity support.
Ask “What makes today 5% easier?” instead of “Did you try thinking positive?”
Hope is important. So is a heating pad, a pharmacy pickup, and someone who listens without cross-examining.

Extended Experience Section (Approx. )

Experience 1: The Engineer Who Couldn’t Sit for a Meeting
A middle-aged engineer with severe lumbar and neuropathic pain had done everything “by the book”: imaging, PT, epidural trials, anti-inflammatories, neuropathic agents, sleep hygiene, and structured exercise.
He wasn’t pain-free, but he was functioningworking half days, coaching his kid’s robotics team, and sleeping five to six hours most nights.
Then a policy shift triggered a rapid medication reduction.
Within weeks, he reported insomnia, escalating pain, panic-like episodes, and missed work.
His chart looked “compliant,” but his life looked like collapse.
After a clinician-led reassessment, care shifted to a gradual, collaborative plan:
slower medication changes, intensified PT, brief pain-focused CBT, and specific function targets.
The breakthrough was not miraculous analgesia.
It was stability.
He returned to part-time work and, importantly, stopped living in fear of the next policy memo.

Experience 2: The Grandmother With CRPS
A retired teacher with complex regional pain syndrome described clinic visits as “defending my humanity in 15-minute increments.”
She was repeatedly told to “just try alternatives,” despite having already tried many.
The missing piece wasn’t motivation; it was access.
Her insurance denied pain psychology and limited PT visits.
She eventually found a team that combined medication management, desensitization therapy, pacing strategies, and telehealth coaching for flare days.
Pain intensity still fluctuated, but her function improved:
she could cook simple meals, attend family events for short windows, and sleep better.
Her biggest quote was memorable:
“I don’t need to win against pain every day. I just need the system to stop fighting me too.”

Experience 3: The Veteran and the Vocabulary Shift
A veteran with multi-site chronic pain and trauma history disengaged from care after feeling judged by language in his records.
He returned when a new clinician changed two things:
first, person-first language; second, explicit shared decision-making.
The plan included functional goals, careful medication review, movement therapy, and regular check-ins focused on what was improving, not just what was wrong.
Over months, emergency visits dropped.
The key clinical intervention may have been trust itself.
When patients feel safe enough to report early warning signs, teams can intervene before crisis.

Experience 4: The Single Parent With EDS
A single parent with connective tissue disorder and chronic widespread pain said the hardest part wasn’t pain aloneit was administrative pain:
prior authorizations, referral loops, pharmacy delays, and constantly re-proving legitimacy.
Her care finally improved when one clinic coordinated everything:
med reconciliation, PT scheduling, work accommodation notes, and follow-up reminders.
No single treatment solved everything.
But coordinated care reduced chaos, and reduced chaos reduced pain amplification.
She put it best: “My nervous system calmed down when my calendar did.”

Experience 5: The Clinician’s Perspective
A primary care clinician described the moral stress of trying to balance safety, policy pressure, and patient suffering.
“I was trained to individualize care,” she said, “but the system rewards me for checkbox outcomes.”
Her clinic redesigned workflows:
longer initial pain visits, interdisciplinary huddles, risk mitigation protocols that avoid punitive framing, and explicit taper safeguards.
Result: fewer ruptured patient relationships, fewer urgent callbacks, and more consistent function gains.
Her conclusion deserves to be on every policy slide:
“When we stop treating every patient as a potential headline and start treating them as a person, outcomes improve.”

Conclusion: End the Binary, Build Better Care

The false choice between “prevent overdose” and “treat severe pain” has harmed patients and burned out clinicians.
We can do both.
The path forward is not ideological.
It is clinical: individualized plans, slow and collaborative dose changes when needed, real access to multimodal care, stigma-free communication, and outcome metrics based on function and safetynot optics.

Stop the war against patients with intractable pain.
Replace it with medicine.
Real medicine: evidence-based, person-centered, and brave enough to be nuanced.